CA2646383A1 - Inhibiteurs de la protease du facteur letal de la toxine anthrax - Google Patents

Inhibiteurs de la protease du facteur letal de la toxine anthrax Download PDF

Info

Publication number
CA2646383A1
CA2646383A1 CA2646383A CA2646383A CA2646383A1 CA 2646383 A1 CA2646383 A1 CA 2646383A1 CA 2646383 A CA2646383 A CA 2646383A CA 2646383 A CA2646383 A CA 2646383A CA 2646383 A1 CA2646383 A1 CA 2646383A1
Authority
CA
Canada
Prior art keywords
phenyl
compound
halo
hydrogen
co2h
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2646383A
Other languages
English (en)
Other versions
CA2646383C (fr
Inventor
Maurizio Pellecchia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanford Burnham Prebys Medical Discovery Institute
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA2646383A priority Critical patent/CA2646383C/fr
Publication of CA2646383A1 publication Critical patent/CA2646383A1/fr
Application granted granted Critical
Publication of CA2646383C publication Critical patent/CA2646383C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
CA2646383A 2008-12-12 2008-12-12 Inhibiteurs de la protease du facteur letal de la toxine anthrax Expired - Fee Related CA2646383C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2646383A CA2646383C (fr) 2008-12-12 2008-12-12 Inhibiteurs de la protease du facteur letal de la toxine anthrax

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2646383A CA2646383C (fr) 2008-12-12 2008-12-12 Inhibiteurs de la protease du facteur letal de la toxine anthrax

Publications (2)

Publication Number Publication Date
CA2646383A1 true CA2646383A1 (fr) 2010-06-12
CA2646383C CA2646383C (fr) 2014-02-11

Family

ID=42238305

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2646383A Expired - Fee Related CA2646383C (fr) 2008-12-12 2008-12-12 Inhibiteurs de la protease du facteur letal de la toxine anthrax

Country Status (1)

Country Link
CA (1) CA2646383C (fr)

Also Published As

Publication number Publication date
CA2646383C (fr) 2014-02-11

Similar Documents

Publication Publication Date Title
US7947717B2 (en) Inhibitors of lethal factor protease
US10905665B2 (en) Chemical modulators of signaling pathways and therapeutic use
AU2007213028C1 (en) Anti-cancer pharmaceutical composition
US7718680B2 (en) Inhibition of lethal factor protease activity from anthrax toxin
NO20171941A1 (en) Methods of treating a neurogenerative disease
CN109790166A (zh) 咪唑并吡啶化合物用于治疗癌症
US20190111052A1 (en) Methods of treating a neurodegenerative disease
CA2838846A1 (fr) Compositions et methodes de traitement d'oedeme cerebral
CA2907603A1 (fr) Derives de 2-amino-ethan-1-one et leur utilisation en tant qu'inhibiteurs de replication virale
KR20190016511A (ko) 히스톤(histone) 탈아세틸화 효소 억제제를 포함하는 조합물
CA2757574C (fr) Inhibiteurs du systeme de secretion de type iii bacterien
US20190070154A1 (en) New methods of use for an anti-diarrhea agent
EP3197888A2 (fr) Antibiotiques autres que les bêta-lactamines
US20110166191A1 (en) 3-(2-amino-ethyl)-5-(3-cyclohexyl-propylidene)-thiazolidine-2,4-dione and its derivatives as multiple signaling pathway inhibitors and for the treatment of cancer
US20220033368A1 (en) Method for making propenamide compound
CN101835747A (zh) 苯并咪唑衍生物
AU2008203743A1 (en) Thioxanthene derivates useful to treat infectious diseases
KR101704386B1 (ko) 티에노[3,2-ｄ]피리미딘 유도체의 Ｔ315Ｉ-Ｂｃｒ-Ａｂｌ 점돌연변이종의 저해 활성
US20170174678A1 (en) Novel antiviral compounds and methods using same
CA2646383C (fr) Inhibiteurs de la protease du facteur letal de la toxine anthrax
AU2008229726B2 (en) Inhibitors of lethal factor protease
US20150073021A1 (en) Chemically modified curcumins as inhibitors of anthrax lethal factor
CN111630052B (zh) 二氢吲嗪酮衍生物
KR20150054231A (ko) Pi3k 저해 활성을 갖는 이미다조피리딘 유도체를 유효성분으로 포함하는 간경화의 예방 또는 치료용 약학적 조성물
US20210179615A1 (en) Niclosamide analogues and therapeutic use thereof

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20210831

MKLA Lapsed

Effective date: 20191212